Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of an upfront payment in cash and equity under a license agreement with Windward Bio AG for the co-development project SKB378/HBM9378/WIN378. This project involves a novel, recombinant fully human monoclonal antibody designed to potently bind to the TSLP ligand and inhibit the TSLP mediated signaling pathway, relevant in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company recently received regulatory approval for an IND application for SKB378/HBM9378/WIN378 in January 2025 for the treatment of COPD from the National Medical Products Administration in China. A phase 1 clinical trial for moderate-to-severe asthma has been completed, and Windward Bio is preparing for a phase 2 trial. However, the company has cautioned shareholders and potential investors that SKB378/HBM9378/WIN378 may not ultimately be successfully developed and commercialized.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.